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Role of Endothelial Shear Stress
in Stent Restenosis and Thrombosis
Pathophysiologic Mechanisms and Implications for Clinical Translation
Konstantinos C. Koskinas, MD, MSC,*† Yiannis S. Chatzizisis, MD, PHD,*†
Antonios P. Antoniadis, MD, PHD,*† George D. Giannoglou, MD, PHD*
Thessaloniki, Greece; and Boston, Massachusetts
Restenosis and thrombosis are potentially fatal complications of coronary stenting with a recognized multifacto-
rial etiology. The effect of documented risk factors, however, cannot explain the preponderance of certain lesion
types, stent designs, and implantation configurations for the development of these complications. Local hemody-
namic factors, low endothelial shear stress (ESS) in particular, are long known to critically affect the natural his-
tory of atherosclerosis. Increasing evidence now suggests that ESS may also contribute to the development of
restenosis and thrombosis upon stenting of atherosclerotic plaques, in conjunction with well-appreciated risk
factors. In this review, we present in vivo and mechanistic evidence associating ESS with the localization and
progression of neointimal hyperplasia and in-stent clotting. Clinical studies have associated stent design fea-
tures with the risk of restenosis. Importantly, computational simulations extend these observations by directly
linking specific stent geometry and positioning characteristics with the post-stenting hemodynamic milieu and
with the stent’s thrombogenicity and pro-restenotic potential, thereby indicating ways to clinical translation. An
enhanced understanding of the pathophysiologic role of ESS in restenosis and thrombosis might dictate hemo-
dynamically favorable stent designs and deployment configurations to reduce the potential for late lumen loss
and thrombotic obstruction. Recent methodologies for in vivo ESS profiling at a clinical level might allow for
early identification of patients at high risk for the development of restenosis or thrombosis and might thereby
guide individualized, risk-tailored treatment strategies to prevent devastating complications of endovascular
interventions. (J Am Coll Cardiol 2012;59:1337–49) © 2012 by the American College of Cardiology
Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.10.903Intracoronary interventions have revolutionized the treat-
ment of coronary artery disease, yet their clinical benefit may
be compromised by in-stent restenosis (ISR) and stent
thrombosis (ST). Several patient-specific characteristics in-
cluding ubiquitous comorbidities, insufficient antiplatelet ther-
apy, and lesion-related and procedural factors including exten-
sive tissue injury and incomplete stent apposition or
underexpansion can precipitate ISR and ST (1). These estab-
lished factors, however, cannot entirely account for the pro-
clivity of certain patients, lesions, or stent types to the devel-
opment of complications. Local hemodynamic factors, low
endothelial shear stress (ESS) in particular, critically affect the
formation, progression, and heterogeneity of atherosclerotic
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accepted October 27, 2011.plaque (2–7). Emerging preclinical (8–12), and clinical (13–
16) evidence now suggests that low ESS may also contribute to
the occurrence of complications upon stenting of atheroscle-
rotic lesions, in conjunction with well-appreciated risk factors.
Stent-induced changes in arterial geometry and, consequently,
in flow and ESS patterns modify the arterial response to
endothelial injury, thereby increasing the risk of ISR and ST.
The purposes of this review are to present in vivo and
mechanistic evidence associating ESS with ISR and ST and to
discuss potential clinical implications of these pathobiological
associations. Enhanced understanding of the pro-restenotic
and prothrombotic effect of adverse ESS patterns may guide
stent designs and implantation configurations with improved
hemodynamic performance, which might translate to im-
proved anatomic and clinical outcomes.
Stent-Induced Changes in ESS
ESS, the tangential stress derived from the friction of flowing
blood on the endothelial surface, is determined by flow velocity
and by the presence of geometric asymmetries or obstructions (2).
Implantation of rigid stent frameworks imposes acute alterations
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etry and creates focal geometric
irregularities related to strut protru-
sion (17). These vascular deforma-
tions modify flow velocity profiles,
reduce the post-implantation ESS
along the entire length of the stent,
and alter the focal in-stent ESS dis-
tribution (18).
In addition to acute, stent-
induced geometric and flow
changes, subsequent neointimal
hyperplasia (NIH) also alters ar-
terial geometry and thereby the
long-term hemodynamic milieu
(19). With the progression of
ISR, local ESS may exhibit temporal changes that are
affected by, and in turn modulate, the neointimal re-
sponse. This dynamic interplay resembles plaque-induced
changes in ESS that dictate additional growth of native
atherosclerotic plaque (Fig. 1) (4,20).
In Vivo Studies Associating Low ESS With ISR
Animal studies. Artificial ESS increase by application of a
flow divider in stented rabbit iliac arteries provided direct
mechanistic evidence that high ESS attenuates NIH
through decreased inflammation, decreased elastic lamina
fragmentation, and decreased smooth muscle cell (SMC)
migration (8). Consistently, the most pronounced NIH
developed in regions with decelerated flow velocity, low
SS, and elevated ESS gradients at implantation (9)
(Fig. 2A). Focal distribution of ISR could thereby be
predicted by the preceding ESS distribution, although the
localization of NIH close to struts might also suggest the
contribution of strut-induced tissue injury to the focal
neointimal response. While these animal studies provide
valuable mechanistic insights into the effect of low ESS on
ISR, direct clinical extrapolation might be limited by
differences in the histology of NIH between animal models
and humans (21).
Human studies. Wentzel et al. (13) first showed an inverse
relationship between ESS magnitude and the extent of ISR
in bare-metal stent (BMS)–treated coronary arteries. In a
serial study by Stone et al. (3), however, NIH at 6-month
follow-up occurred at virtually all levels of baseline ESS.
Methodological differences mainly regarding flow measure-
ment might explain the contradictory results of these 2
pioneer studies. Later investigations consistently demon-
strated an inverse relationship between ESS and ISR after
BMS implantation (14,15,22) (Fig. 2B). Notably, ISR did
not develop in all low-ESS sites, and, conversely, not all
sites of ISR originated from low-ESS regions in these
studies, likely indicating the contribution of other factors,
such as lesion complexity, plaque inflammation, and the
Abbreviations
and Acronyms
BMS  bare-metal stent(s)
DES  drug-eluting stent(s)
ESS  endothelial shear
stress
ISR  in-stent restenosis
MB  main branch
NIH  neointimal
hyperplasia
SB  side branch
SMC  smooth muscle cell
ST  stent thrombosismagnitude of direct tissue injury. Regarding drug-elutingstents (DES), ISR occurred more extensively in low-ESS
regions after sirolimus-eluting stent (16) and paclitaxel-
eluting stent (23) implantation. Only 1 relevant study
found no relationship between ESS and neointimal
thickening in sirolimus-eluting stent–treated lesions (24),
which was likely related to the patients’ diabetic status in
that investigation.
Role of Low ESS in the
Pathobiology of Restenosis
NIH represents an excessive healing response to endothelial
injury. Migration of SMCs, the main cellular substrate of
NIH, is dictated by injury-induced inflammation (25) and is
affected by several risk factors of ISR (1). Low ESS likely
exerts a synergistic pathobiological effect in this process
(Fig. 1C). With BMS implantation, by which the endothe-
lium is restored within weeks after implantation, low ESS
conceivably promotes ISR through interactions of shear-
sensing endothelial cells with SMCs (26). With DES
implantation, by which re-endothelialization is retarded
pharmacologically (27–30), ESS may act on SMCs directly
via endothelium-independent mechanisms.
Endothelium-mediated effect of low ESS. Low ESS
up-regulates proinflammatory genes, including adhesion
molecules, chemoattractant chemokines, and cytokines (2),
hereby enhancing injury-induced inflammation. In addi-
ion, low ESS promotes the activation, proliferation, and
igration of SMCs by increasing the expression of platelet-
erived growth factor (31), endothelin-1, and vascular-
ndothelial growth factor and by attenuating endothelial
xpression of plasminogen activator inhibitor 1, an inhibitor
f SMC migration (32).
ndothelium-independent effect of low ESS. SMCs per
e are responsive to hemodynamic flow (33). Vasculopro-
ective laminar flow inhibits SMC proliferation and migra-
ion (34) by down-regulating platelet-derived growth factor
nd by promoting the autocrine effect of transforming growth
actor-, a potent SMC proliferation suppressor (35). Con-
versely, low ESS promotes SMC proliferation and migration,
independently of the effect on endothelial cells (36).
Effect of low ESS on SMC phenotype. Neointimal
SMCs shift from a quiescent, contractile phenotype to a
synthetic phenotype. The phenotype of SMCs is clini-
cally highly relevant because synthetic SMCs produce
more extracellular matrix molecules and thus add more to
the neointimal buildup. Low ESS favors synthetic SMCs
(37) through up-regulation of the SMC differentiation
repressors platelet-derived growth factor and KLF-4 (38)
and thereby amplifies the naturally occurring synthetic
state of neointimal SMCs.
Modifiable Factors That Influence
the Pro-Restenotic Effect of Low ESS
Stent type: BMS versus DES. Evidence exists that low
ESS exerts a differential pro-restenotic effect in BMS
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extensive ISR with BMS placement likely sustains and
amplifies disturbed flow and restenosis-induced low ESS,
which might favor additional NIH (19). By inhibiting ISR
pharmacologically, DES attenuate restenosis-related flow
disturbances, thereby creating a hemodynamic environment
with inherently lower pro-restenotic potential. In addition,
the pro-restenotic effect of low ESS on DES may be
abolished by the effect of flow on drug release (40).
Recirculation zones with reduced flow and low ESS, typi-
cally distal to stent struts (18), prolong the residence time
Figure 1 Proposed Role of Low ESS in In-Stent Restenosis
(A) Plaque-induced low ESS promotes plaque growth downstream of lumen-protruding
lesser extent, DES-treated lesions. (C) Schematic presentation of the interrelationship
with permission, from Koskinas et al. (20). (B) Adapted, with permission, from Richte
shear stress; ET  endothelin; PAI  plasminogen activator inhibitor; PDGF  platelet-and increase local concentration of the eluted compound. Insuch regions with decelerated flow, the locally augmented
antiproliferative drug effect might thereby antagonize the
pro-restenotic effect of low ESS per se.
Stent drug. Certain eluted drugs may attenuate the neointimal
response to low ESS. SMC cell cycle is regulated by a balance
between positive regulators, including cyclins and cyclin-
dependent kinases, and negative regulators, including cyclin-
dependent kinase inhibitors. Sirolimus inhibits SMC migration
by decreasing cyclin-dependent kinase and increasing cyclin-
dependent kinase inhibitor activity (41). Importantly, low ESS
may antagonize these sirolimus effects (42) by up-regulating
sclerotic lesions. (B) Restenosis (*) imposes flow disturbance in BMS- and, to a
en restenosis and low ESS that may promote additional restenosis. (A) Adapted,
(19). BMS  bare-metal stent(s); DES  drug-eluting stent(s); ESS  endothelial
growth factor; SMC  smooth muscle cell; VEGF  vascular endothelial growth factor.athero
betwe
r et al.
derivedcyclin-dependent kinase–mediated SMC proliferation (43). In
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somal impairment, independently of ESS-related signaling
pathways. Consistently, clinical restenosis is low ESS-related
in lesions with BMS and paclitaxel-eluting stents, but not in
Figure 2 In Vivo Evidence Associating
Low ESS With In-Stent Restenosis
(A) In-stent ESS distribution predicts subsequent localization of neointimal
hyperplasia (NIH) in rabbit iliac arteries. Regions adjacent to struts are
exposed to low ESS (middle). Histological sections (top and bottom) colocal-
ize low-ESS regions with pronounced NIH. Asterisks indicate locations of
struts. Spatial plots of ESS and NIH display the correlation between ESS
and NIH distribution. (B) 3-dimensional color-coded maps show in-stent
ESS distribution (left) and neointima thickness (right) in a human coronary
artery. Low-ESS regions (circles) colocalize with increased neointima thick-
ness. ESS  endothelial shear stress; WSS  wall shear stress. (A)
Adapted, with permission, from LaDisa et al. (9). (B) Adapted, with permis-
sion, from Papafaklis et al. (14).lesions treated with sirolimus-eluting stents (39). Althoughthe antiproliferative capacity of sirolimus is primarily related
to its cytostatic impact on SMCs, attenuation of the
pro-restenotic effect of low ESS in regions with restenosis-
susceptible anatomy might represent an additional beneficial
effect of sirolimus over paclitaxel.
Different DES types differentially affect the phenotype
and thereby the matrix-producing capacity of neointimal
SMCs. Sirolimus favors contractile SMCs, whereas pacli-
taxel promotes synthetic SMCs in vitro (44) and in vivo
(45). Therefore, sirolimus likely attenuates, whereas pacli-
taxel amplifies, the low ESS–induced synthetic phenotype
of SMCs. The interrelating effects of ESS and other DES
types on SMC phenotype are unexplored and may merit
investigation.
Stent design. Computational, experimental, and clinical
investigations strongly support a critical impact of stent
design on the in-stent ESS and on the development of ISR.
The mere presence of struts imposes flow separation and
recirculation zones downstream of struts. The magnitude of
these stent-induced flow disruptions is largely dependent on
strut design (10,18,46) and, in turn, substantially influences
the arterial response to stenting in animal models (9,47,48).
These observations become particularly important when
coupled with clinical evidence concerning different rates of
ISR attributed to different stent geometries. Strut shape,
strut thickness, and the arrangement of strut-strut intersec-
tions have been associated clinically with the angiographic
severity of ISR and with post-intervention clinical outcomes
(49–54). Among different stents, those with hemodynam-
ically favorable designs according to computational modeling–
based simulations are robustly associated with reduced
ISR in clinical practice (Figs. 3A to 3D) (55). Although
these computational predictions underscore the impact of
stent design on the ESS distribution and pro-restenotic
potential (55), extrapolation to the in vivo setting may be
limited by the effect of patient-specific characteristics on
clinical restenosis.
Of potential clinical value for integration of these con-
cepts in interventional practice, the adverse hemodynamic
consequences of stenting are amenable to stent design.
Strut-induced flow disruption can be attenuated by the
combination of reduced strut thickness and streamlined
strut shape (10,11). Thick struts increase the in-stent area
exposed to low ESS, whereas thinner struts and larger
interstrut spacing restore ESS to physiologic levels (10). In
addition, flow separation, low ESS, and spatial ESS gradi-
ents in the vicinity of struts are more pronounced with
rectangular (nonstreamlined) struts, they are reduced with
circular arc-shaped (streamlined) struts with a 2:1 width-
to-height ratio, and virtually abolished by thinner stream-
lined struts with 4:1 and 8:1 width-to-height ratios (Fig. 3E) (10).
Quantification of the effect of strut design on the in-stent
ESS affirmed that streamlined struts yielded only 4% of
between-struts area exposed to low ESS, whereas non-
streamlined struts dramatically increased the low ESS area
to 81% (11). Appreciating the synergistic beneficial effect of
1341JACC Vol. 59, No. 15, 2012 Koskinas et al.
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Wall shear stress (WSS) is lower (A), WSS gradients are higher (B), and the percentage of between-struts area with low WSS is greater (C,D) for the Wallstent com-
pared with the BxVelocity, Aurora, and NIR stents. (E) Streamlines at the vicinity of rectangular (nonstreamlined) struts (left) and circular arc (streamlined) struts (right)
for 2:1, 4:1, and 8:1 length-to-height ratios. Recirculation zones occur in rectangular struts for all aspect ratios, but only in thick circular-shaped struts with a 2:1 length-
to-height ratio. (A to D) Adapted, with permission, from Duraiswamy et al. (55). (E) Adapted, with permission, from Jimenez and Davies (10).
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have considerable implications in optimizing hemodynam-
ically favorable stent designs because the maximal extent of
strut thinning per se is limited by the need to maintain
adequate material strength.
In addition to strut design, strut connectors also affect
in-stent hemodynamics. Computational comparison of 5
clinically used stents showed that minimal connector length
in the cross-flow direction and optimal alignment with flow
decreased the percentage of in-stent area exposed to low
ESS (56).
Stent diameter. Stents with increased diameter relative
to the normal artery cross section pose a higher risk of
clinical ISR (57). Although stent oversizing may induce
ISR through marked arterial injury, oversized stents may
also promote NIH by increasing the arterial cross section,
reducing flow rate, and thus lowering ESS in the stented
versus the proximal nonstented arterial segment.
Stent undersizing may also favor ISR by creating low-
ESS zones near struts. Intriguingly, simulations comparing
Figure 4 Effect of Stenting Configuration on the Post-Stenting
(A) Different implantation configurations of an everolimus-eluting (XCIENCE) stent:
ESS magnitude at the upstream (a), mid stent 1 (b), mid stent 2 (c), and downst
compared with the same location in the single long stent. (C) Photomicrograph of
overlapping Palmaz-Schatz stents. Note the enhanced NIH at the region of stent o
Adapted, with permission, from Ellis et al. (63). Abbreviations as in Figures 1 anddifferent scenarios of stent undersizing indicate more
marked decrease in ESS for 5% stent undersizing compared
with 20% undersizing (12). Mechanistically, minor stent
undersizing creates small gaps between the struts and the
arterial wall, thereby increasing flow resistance and lowering
local ESS. In the case of more pronounced stent undersiz-
ing, the increased distance between stent struts and the wall
may attenuate the effects of flow resistance and ESS
lowering (12). These computational observations under-
score the impact of optimal stent size selection on the
post-stenting hemodynamic environment and likely account
in part for the clinical association of underexpansion and
incomplete stent apposition with ISR (58) and thrombotic
complications (59).
Stenting configuration. In addition to stent design, stenting
configuration decisively influences in-stent hemodynamics. Vir-
tual implantation of an everolimus-eluting stent (XCIENCE-V,
Abbott Vascular, Santa Clara, California) in 5 configurations
yielded marked heterogeneity of ESS distribution among
different implantation scenarios (60). Implantation of 2
l, long, and 2 overlapping stents. (B) Stenting configuration differentially affects
d) locations. ESS is substantially lower distal to the stent overlap (arrowheads)
az-Schatz BMS. (D) Autopsy specimen from an artery previously treated with 2
(arrows). (A, B) Adapted, with permission, from Charonko et al. (60). (C, D)ESS
norma
ream (
a Palm
verlap
2.
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April 10, 2012:1337–49 Shear Stress, In-Stent Restenosis, and ThrombosisFigure 5 Hemodynamic and Neointimal Responses to Single Versus Double Stenting in Coronary Bifurcations
(A) Computational model of ESS distributions under resting (top) and hyperemic flow (bottom) in the main branch (MB) and side branch (SB) of a bifurcation treated
with different stenting configurations. Best and worst stent position indicate the least and the greatest number of struts obstructing the SB ostium, respectively. SB
angioplasty after MB stenting (right) does not significantly modify the area with low WSS compared with MB stenting alone. (B) Serial sections along the stented MB in
a pig coronary bifurcation. NIH is more pronounced in the case of a patent SB (upper panels and in vivo corresponding angiogram) compared with the occluded SB case
(lower panels). (C) Pre-stenting (left) and post-stenting (middle) angiographic images in a human coronary bifurcation treated with 2 stents. Six-month follow-up (right)
shows restenosis at the ostium of the SB. (A) Adapted, with permission, from Williams et al. (71). (B) Adapted, with permission, from Richter et al. (70). (C) Adapted,
with permission, from Colombo et al. (74). Abbreviations as in Figure 2.
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of the junction compared with a single longer stent, likely
indicating a region prone to renarrowing at the overlap
zone (60) (Fig. 4). Stent overlap has been associated with
marked inflammation and poor endothelialization (61)
and with unfavorable angiographic and clinical outcomes
(62,63). Although the increased drug and polymer con-
centration at the site of double-stent layers may locally
increase tissue toxicity and precipitate neointimal growth
(64), the adverse hemodynamic sequelae of stent overlap-
ping might also contribute to the higher risk of ISR in
this setting (60).
Long coronary stents have also been linked to late lumen
loss and worsening clinical prognosis (49,65). Long stents
do not impose significant flow disruption compared with
shorter stent lengths (60). The higher ISR rates observed
clinically with longer stents might therefore relate to lesion
complexity, greater vascular injury, or adverse clinical char-
acteristics of patients presenting with longer lesions rather
than to the hemodynamic effect of long stents. From a
hemodynamic perspective, a single longer stent rather than
Figure 6 Stent Thrombosis Localizes in Regions With Disturbed
(A) Postmortem angiogram of a BMS-stented left anterior descending (LAD)–left d
(arrow) and platelet-rich thrombus around an uncovered strut (*). (D) Bifurcation
stents are occluded with thrombus (Thr) adherent to uncovered struts at the flow d
stented model (I) versus vortical structures (arrows) at the flow divider in the sten
Adapted, with permission, from Nakazawa et al. (69). LM  left main; other abbremultiple overlapping stents might therefore be preferable, if
technically feasible, for the treatment of long or diffuse
plaques.
Arterial curvature. Inflexible stents that do not conform to
the natural arterial curvature impose skewing of velocity
profiles (13,17) and decrease ESS along the myocardial
aspect of the stented segment (18). These adverse hemody-
namic sequelae of implanting inflexible stents in curved
coronary segments might account for the clinical associ-
ation of stent-imposed arterial straightening with angio-
graphic ISR and adverse clinical events (66). Importantly,
resorption of the stent polymer in recently introduced
bioabsorbable vascular scaffolds gradually restores arterial
curvature to the pre-implantation state (67). These
promising platforms might thereby in the long-term
ameliorate the adverse ESS changes of arterial straight-
ening imposed at implantation.
Bifurcation stenting. Bifurcation lesions predispose to
ISR (1), likely due to the inherently complex geometry
and flow patterns that are further complicated by the
intervention itself (68). NIH in DES-treated coronary
l (LD) bifurcation. (B, C) Histopathology shows thrombosis with neointima
treated with 2 DESs in the LAD and left circumflex (LCX) ostia. (E to G) Both
. (H to J) In vitro model in the same study shows undisturbed flow in the non-
odel (J). (A to C) Adapted, with permission, from Farb et al. (27). (D to J)
s as in Figure 1.Flow
iagona
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walls compared with the high-ESS flow divider in
autopsy registries (69). Consistently, leukocyte accumu-
lation and subsequent neointimal buildup localize at the
lateral walls of stented coronary bifurcations in pigs (70),
clearly suggesting a link among local low ESS, inflam-
mation, and focal ISR.
Of clinical importance, the hemodynamic sequelae of
different bifurcation stenting techniques may appreciably
affect local ESS and the proclivity to ISR. Although the
widely applied side-branch (SB) angioplasty after main-
branch (MB) stenting is beneficial in terms of restoring
flow patency, there may not be a benefit to this approach
compared with MB stenting alone from a hemodynamic
perspective (Fig. 5A) (71). Consistently, experimental
ISR in the stented MB of a coronary bifurcation was
more pronounced with concomitant dilation of the occluded
SB compared with the untreated SB scenario (Fig. 5B) (70).
Mechanistically, flow in the obstructed MB may be opti-
mized functionally in the occluded SB state. Consequently,
flow disruption imposed on the stented MB by concomi-
tantly opening the SB might in the long-term outweigh the
immediate benefit of restoring flow patency in both
branches (70). The lack of hemodynamic benefit by SB
angioplasty compared with MB stenting alone might, at
least in part, account for the lack of significant clinical
benefit of double versus single stenting of bifurcation lesions
with BMS (72) or DES (73,74) (Fig. 5C).
In bifurcations treated with DES, relative stent position-
ing may modify the neointimal response by altering flow-
mediated drug kinetics within the bifurcation. Computa-
tional simulations indicate higher drug delivery in the
stented MB for the mid-and downstream compared with
the upstream position of the stent relative to the bifurcation
entrance. The clinically relevant increase in drug elution in
the former scenario of stent positioning is likely related to
the overlap of the drug-coated stented segment with the
region of boundary layer separation (75).
Overall, although decision making for the treatment of
individual bifurcation lesions is clearly dictated by anatomic
and functional lesion characteristics and by patient-specific
criteria (76), consideration of hemodynamic parameters may
optimize local drug delivery and might guide stenting
configurations with improved long-term outcomes.
Role of ESS in ST
Clinical evidence associating ESS with ST. Contrary to
the progressive nature of ISR, the abrupt occurrence of
clotting hampers the prospective assessment of ST in
relation to local hemodynamics. Pathologic studies suggest
that stenting across branch ostia and bifurcations (i.e.,
regions with disturbed flow) precipitate ST in BMS (27)
and DES (28) (Figs. 6A to 6C). Clotting occurs at sites
with delayed arterial healing and incomplete strut coverage
that colocalize with vortical flow structures, mainly at theflow divider (69) (Figs. 6D to 6J). Overall, although arterial
regions exposed to nonphysiologic ESS appear conducive to
ST in autopsy registries, associations with in vivo responses
are indirect and therefore cannot establish causality.
Potential role of ESS in the pathobiology of ST. The
pathobiology underlying ST is multifaceted. Although sys-
temic factors, including patient-specific characteristics and
inadequate antiplatelet therapy, play a major role (1), certain
local stent-related and procedural factors may also precipi-
tate ST, in part via their adverse effect on local ESS
(Table 1). Notably, stent thrombogenicity may be aug-
mented by low ESS–induced endothelial dysfunction and
also by high ESS–induced platelet activation.
ENDOTHELIUM-RELATED PRO-THROMBOTIC EFFECT OF ESS.
Thrombosis is prevented in normal arteries by a balance
among prothrombotic and antithrombotic factors. Low ESS
attenuates the endothelial expression of nitric oxide, prostacy-
clin I2, and tissue plasminogen activator, shifting the balance
oward a prothrombotic state (2). Additionally, low ESS may
romote ST by inhibiting endothelial cell proliferation and
etarding re-endothelialization of the arterial and strut surface
Risk Factors of Late StentThrombosis and Poten ial Role of ESSTable 1 Risk Factors of Late StentThrombosis and Potential Role of ESS
Risk Factor
Effect on In-Stent ESS/
Endothelial Response to ESS
Patient factors
Diabetes
Renal failure
Acute coronary syndrome
Stent factors
Incomplete endothelialization ¡ Attenuation of physiologic
ESS-induced endothelial
production of PGI2, tPA,
eNOS (2)
Hypersensitivity to the drug or polymer
Procedural factors
Bifurcation stenting ¡ Adverse hemodynamic
impact on the inherently
complex ESS environment
(68–70)
Lesion complexity
Multivessel disease
Excessive stent length
Stent undersizing ¡ Gaps between stent struts
and arterial wall ¡
increased flow resistance
¡ low ESS (12)
Incomplete stent expansion (underexpansion)
Overlapping stents
Expansive vascular remodeling ¡ Reduced flow rate ¡ low
ESS (2,4)
Antiplatelet therapy
Premature discontinuation
Clopidogrel resistance
Certain recognized risk factors of late stent thrombosis, indicated in bold, likely act in part by
adversely modulating the in-stent ESS or by affecting the response of the endothelial substrate to
the local ESS.eNOS endothelial nitric oxide synthase; ESS endothelial shear stress; PGI2 prostacyclin I2;
tPA  tissue plasminogen activator.
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ical correlate of ST (27–29), favors ST by exposing throm-
bogenic arterial components (metallic stent material, lipid
core) to circulating prothrombotic factors. Although DES,
in particular, delay re-endothelialization pharmacologically,
low ESS might exert a synergistic effect and may thereby
extend the timeframe during which DES are prone to ST.
PLATELET-RELATED PRO-THROMBOTIC EFFECT OF ESS.
Stenting creates regions with accelerated flow and high ESS
on top of the struts and low ESS downstream of the struts;
both sites of nonphysiologic ESS may enhance stent throm-
bogenicity. ESS peaks over the strut surface edges activate
platelets to release thromboxane A2 and adenosine diphos-
phate, which are potent mediators of platelet aggregation.
Erythrocytes exposed to high ESS also release adenosine
diphosphate. Activated platelets enter flow separation zones
downstream of struts, reach high concentrations due to delayed
flow, and, assisted by the low ESS–mediated attenuation of
native anticoagulants, may trigger the coagulation cascade.
Modifiable factors that influence the prothrombotic ef-
fect of ESS. STENT TYPE: BMS VERSUS DES. DES have been
perceived to inherently increase the likelihood of late ST
Figure 7 Effect of Strut Design on Stent Thrombogenicity
(A) Thick, rectangular struts promote stent thrombogenicity. High ESS on top of s
aggregation promoter. Recirculation zones with low ESS downstream of the strut i
attenuate the production of natural anticoagulants. (B) Thin, circular struts retain
re-endothelialization and production of antithrombotic factors downstream of stru
lial shear stress; NO  nitric oxide; PGI2  prostacyclin; tPA  tissue plasmin
nez and Davies (10).based on extensive clinical (58,78) and autopsy findings
(27–29,69). This notion has been challenged, however, by
some contradictory clinical results (79). Intriguingly,
DES may actually decrease early thrombogenicity com-
pared with BMS in experimental (80) and clinical set-
tings (81). The synergistic effects of adverse stent design
features, particularly greater strut thickness, and stent
positioning, such as malapposition and overlapping,
rather than drug coating per se, are likely the key determinants
of stent thrombogenicity (80).
STENT DESIGN. The creation and localization of thrombosis-
prone regions are dictated by, and therefore amenable to,
certain stent design characteristics. Thicker and nonstream-
lined stent designs, such as currently applied rectangular
geometries, may precipitate ST by: 1) magnifying high
ESS–induced platelet activation on top of struts; and
2) impeding re-endothelialization, thus attenuating the
endothelial production of anticoagulants in low-ESS re-
gions downstream of struts (Fig. 7). The extent of de-
endothelialization downstream of struts is proportional to
strut thickness (28), likely due to more intense flow distur-
bance and greater flow separation distance induced by
ctivates platelets to release adenosine diphosphate (ADP), a potent platelet
e local concentration of activated platelets, retard re-endothelialization, and
logic ESS, which favors platelet quiescence on top of struts and enhances
d circle  activated platelet; Red line  quiescent platelet. ESS  endothe-
activator; vWF  von Willebrand factor. Modified, with permission, from Jime-truts a
ncreas
physio
ts. Re
ogen
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clinically used stents affirm increased platelet deposition in
nonstreamlined strut designs that produce complex flow
patterns (82).
Clinical Implications of
Applying In Vivo ESS Profiling and
Hemodynamically Favorable Stent Designs
Several patient-specific, lesion-related, and procedural fac-
tors are known to precipitate ISR and ST (1), yet the
identification of patients at highest risk of experiencing
these complications remains a major clinical challenge.
Multiple lines of experimental and clinical evidence extend
our current understanding of low ESS as a proatherogenic
stimulus (2–7) to a factor that also contributes to ISR and
ST, clearly in conjunction with established risk factors.
Appreciation of stent design and implantation configuration
as critical determinants of the post-implantation hemody-
namic milieu in a given local anatomy might therefore have
significant implications in guiding individualized interven-
tions with improved anatomic and clinical outcomes. In
BMS, attenuation of restenosis-prone flow disruptions by
integration of hemodynamically favorable stent design and
positioning might reduce NIH in the early post-stenting
period. In DES, optimal design properties could minimize
disturbed flow patterns that likely retard re-endothelialization
and precipitate late ST. Consideration of local hemodynamic
as well as anatomic parameters in bifurcation lesions might
optimize the post-stenting ESS distribution and in-stent drug
kinetics in this challenging lesion subset. Recent bioabsorbable
vascular scaffolds that gradually restore native arterial geometry
might attenuate the stent-imposed adverse changes in ESS and
might thereby improve long-term outcomes.
Early investigations of the role of ESS in vascular
behavior were limited at the in vitro and ex vivo levels.
Methodological advances have now enabled in vivo profiling
of in-stent ESS in large-scale clinical studies (PREDICTION
trial) (83), suggesting that these methods might become
suitable for clinical purposes (84). In vivo characterization of
in-stent regions with particularly low ESS might enable
identification of individual patients and individual stented
lesions prone to subsequent development of ISR or ST. In
the emerging era of tailoring post-stenting adjunctive ther-
apy (85), integration of intracoronary hemodynamics in the
catheterization laboratory might allow for risk-tailored
stenting strategies to avert the rare yet devastating compli-
cations of coronary interventions.
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